<DOC>
	<DOCNO>NCT00541840</DOCNO>
	<brief_summary>Soft tissue sarcoma ( STS ) uncommon group malignant tumor mesenchymal origin . For advanced STS type , chemotherapy currently available treatment . Unfortunately , limited number useful drug active disease . Doxorubicin widely consider standard first-line treatment . Ifosfamide also well-established activity ( 1,2 ) often administer either associate Doxorubicin alone second-line chemotherapy treatment . Other drug DTIC , Gemcitabine Temozolomide show modest activity second-line agent ( 3,4 ) . Thus , necessity identify new agent activity improve therapy patient advanced STS . In study , STS show VEGF expression , elevate serum VEGF level find correlate high histologic tumor grade ( 5,6 ) . Additionally , inhibition VEGFR associate tumor activity preclinical model sarcoma ( 7,8 ) . For reason , inhibition VEGFR seem reasonable approach explore treatment STS . Sorafenib ( BAY 43-9006 ) orally available , small molecule multi-kinase inhibitor VEGFR , PDGFR RAF demonstrate activity treatment renal cell cancer ( 9 ) . Preclinical study suggest combination Sorafenib cytotoxic agent result additive anti-tumor activity ( 10 ) , initiate justification combination study . A recent trial , however , report unexpected incidence cardiac toxicity patient STS treat Bevacizumab , monoclonal antibody bind VEGF , combination Doxorubicin ( 11 ) . This finding suggest possibility potentiation cardiotoxicity Doxorubicin inhibit VEGF pathway rule . The association Sorafenib Ifosfamide , establish active agent STS , could improve efficacy single-agent Ifosfamide minimizing risk cardiac toxicity .</brief_summary>
	<brief_title>Phase I-II Trial Sorafenib Combination With Ifosfamide Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Advanced Soft Tissue Sarcoma histologically proven , exclude follow subtypes : chondrosarcoma , osteosarcoma , Ewing 's sarcoma , embryonal rhabdomyosarcoma . 2 . Patients must previously treat Anthracycline . However , patient eligible Anthracycline treatment included.Prior treatment Ifosfamide allow , except administer adjuvant therapy . 3 . Patients must &gt; 18 &lt; 72 year old . 4 . Patients must ECOG performance status 0 1 fase I . 5 . Patients must ECOG performance status 0 2 fase II . 6 . Patients must measurable disease . Progression must document last month prestudy entry . No prior radiotherapy indicator lesion allow . 7 . Adequate bone marrow , renal hepatic function hemoglobin ³ 9.0 g/dl absolute neutrophil count ³ 1,500/mm3 platelet count ³ 100,000/mm3 total bilirubin £ 1.5 time upper limit normal ALT AST £ 2.5 time upper limit normal ( £ 5 x upper limit normal patient liver involvement ) INR £ 1.5 aPTT within normal limit serum creatinine £ 1.5 upper limit normal 8 . Signed informed consent prior study specific procedures 1 . Patients previous chemotherapy radiotherapy , within 3 week prior study entry . 2 . Pregnant breast feeding patient . Women childbearing potential must negative pregnancy test perform within 7 day prior start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial . 3 . Life expectancy le 12 week . 4 . General medical psychological condition would preclude appropriate inform consent compliance protocol . 5 . Substance abuse , medical , psychological social condition may interfere patient participation study . 6 . Previous cancer distinct primary site histology NSCLC except cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor ( Ta Tis ) cancer curatively treat &gt; 3 year prior study entry . 7 . Concurrent treatment anticancer therapy . 8 . Concurrent treatment experimental drug ( within 30 day prior study entry ) . 9 . Significant weight loss ( &gt; equal 10 % body weight precede 6 week ) . 10 . Major surgery , open biopsy significant traumatic injury within 4 week first dose study drug . 11 . Biological modifying agent GCSF administer within 3 week prior study entry . 12 . Known suspected allergy sorafenib ifosfamide . 13 . Evidence history bleed diathesis coagulopathy . 14 . Therapeutic anticoagulation Vitamin K antagonists warfarin heparin heparinoids . Low dose warfarin permit INR &lt; 1.5 . Low dose aspirin permit . 15 . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . 16 . Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management . 17 . Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina newonset angina ( begin within last 3 month ) myocardial infarction within last 6 month . 18 . Active clinically serious infection &gt; CTCAE Grade 2 . 19 . Serious , nonhealing wound , ulcer , bone fracture . 20 . Concomitant treatment ketoconazole , itraconazole , ritonavir , rifampicin St. John´s Wort . 21 . Known HIV infection chronic hepatitis B C. 22 . Known brain metastasis . Patients neurological symptom undergo CT scan/MRI brain exclude brain metastasis . 23 . Any condition could compromise patient 's security and/or study 's fulfilment . 24 . Known suspected allergy mesna tiolic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>GEIS</keyword>
</DOC>